EAVI2020 EAVI2020 on Twitter EAVI2020 on Facebook EAVI2020 on LinkedIn

International AIDS Vaccine Initiative Inc (IAVI Inc)

International AIDS Vaccine Initiative Inc (IAVI Inc) was established in 1996 and is a global not- for-profit, public private partnership with the mission to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. IAVI’s European office is located in Amsterdam, Holland, the Human Immunology laboratory is based in London, United Kingdom and the US headquarters are in New York.

Activities provided by the IAVI VxPDC in support of the consortium will be across the development process. A VxPDC project team will be formed to provide the PI and the consortium with the relevant skills necessary to support GMP manufacture of Vaccine Vectors and Recombinant Proteins respectively, and providing advice and plans for pre-clinical safety assessments, guidance, advice and conduct of audits for Contract Manufacturing Organisations (CMOs) and Contract Research Organisations

https://www.iavi.org/

Dr Jill Gilmour

The IAVI Human Immunology Laboratory, a partnership with Imperial College London, will be one of the laboratories assessing immune responses induced in EAVI2020’s clinical trials. IAVI will also provide product development support to help the consortium’s vaccine candidates advance through clinical assessment. Dr. Jill Gilmour [Executive Director, Human Immunology Laboratory] and Dr. Thomas Hassell, IAVI Vice President, Vaccine Development, are the primary investigators leading IAVI’s work in EAVI2020.

Deborah King

d.king@imperial.ac.uk